Lexeo Therapeutics, Inc. announced it has entered into a common stock purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 6,278,905 shares of its common stock at an issue price of $15.13 per share for gross proceeds of $95,000,000 on March 11, 2024. the transaction will include participation from Braidwell LP, Adage Capital Partners LP, RA Capital Management, Surveyor Capital, Eventide Asset Management and Novo Holdings A/S. The transaction is expected to close on March 13, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.64 USD | -3.75% |
|
-14.02% | +16.54% |
Jun. 13 | Baird Initiates Lexeo Therapeutics With Outperform Rating, $28 Price Target | MT |
Jun. 06 | HC Wainwright Initiates Lexeo Therapeutics at Buy With $22 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.54% | 515M | |
+34.01% | 51.07B | |
+34.63% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding